Table 3.
The AEC outcome, depending on the clinical response to ICI.
| AEC follow-up | Clinical responders | Non-responders | |
|---|---|---|---|
| n = 19# | n = 10# | ||
| CHR | n (%) | 11 (58%) | 7 (70%) |
| Treated with CSs | 4 | 5 | |
| PHR | n (%) | 3 (16%) | 2 (20%) |
| Treated with CSs | 1 | 0 | |
| Stable AEC1 | n | 4 (21%) | 0 |
| Increased AEC2 | n | 1 (5%) | 1 (10%) |
ICI: immune checkpoint inhibitor; AEC: absolute eosinophil count; CHR: complete hematologic remission with AEC < 0.5 G/L; PHR: partial hematologic remission, with AEC > 0.5 G/L and a decrease in the AEC of >50%;:1 AEC between 50% and 150% of baseline AEC;:2 AEC > 150% of baseline AEC or unstable; CS: corticosteroid; #: nine patients with missing data.